Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“SKB BIO”) filed its Monthly Return for Equity Issuer covering the period to 31 August 2026.

Authorised / Registered Capital • Aggregate authorised share capital remained unchanged at RMB 239.02 million, comprising 176.82 million H shares and 62.20 million domestic shares, each with a par value of RMB 1.

Issued Shares and Treasury Shares • Issued H shares: 176.82 million; Domestic shares: 62.20 million. • No new shares were issued, cancelled, or repurchased during the month; treasury share balance stayed at zero.

Public Float • The company confirmed compliance with the Hong Kong Main Board’s minimum public-float requirement of 22.09 % of H-share class issued capital as of 31 August 2026.

Share-Based Incentives • Under the 2025 Share Incentive Scheme, a total of 435,064 restricted share units approved on 31 December 2025 remain available for future issuance; none were allotted in August 2026.

Regulatory Confirmation • SKB BIO affirmed that all statutory filings and listing rule obligations relating to its securities remain fully satisfied. The return was submitted on 3 September 2026 by Company Secretary Zhou Zejian.